USPTO serial 98091758
IBIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 24, 2024
- Examiner
- BONEN-CLARK, HOPE MICHELLE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with IBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA
San Diego, CA
San Diego, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Daniel Chalker
Daniel Chalker CHALKER FLORES, LLP14841 DALLAS PARKWAY, SUITE 575DALLAS, TX 75254United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Pharmaceutical peptide, protein, antibody, and chimeric antibody or protein drug development services; Pharmaceutical peptide, protein, antibody, and chimeric antibodies or proteins product development; Pharmaceutical research and development of peptides, proteins, antibodies, and chimeric antibodies or proteins; Conducting early evaluations in the field of new peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical preparations and medicines; Laboratory peptide and protein based research services relating to pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Research on the subject of peptide, protein, antibody, and chimeric antibody or protein based pharmaceuticals; Technical research in the field of peptide, protein, antibody, and chimeric antibody or protein based pharmaceutical studies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff made with peptides, proteins, antibodies, and chimeric antibodies or proteins; Research and development in the pharmaceutical and biotechnology fields; Research and development regarding pharmaceuticals, proteins, and antibodies; platform-as-a-service (PaaS) featuring computer software platforms for protein analysis and discovery of antibody-based drugs; Software as a service (SAAS) services featuring software for designing molecule libraries for the purposes of generating products in the field of pharmaceuticals, biotechnology, and medicine; Computer software development in the field of artificial intelligence, biotechnology, pharmaceuticals, and medical applications; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing on-line non-downloadable software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Scientific research for medical purposes in the area of cancerous diseases; Software as a service (SAAS) services featuring software using artificial intelligence for use in facilitating product development in the field of biotechnology, pharmaceuticals, and medicine; Technical consulting in the field of pharmaceutical studies; Technology consultation in the field of artificial intelligence; Testing of pharmaceuticals; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical testing services and information in the field of cancer research and disease classification; Providing information about medical research in the field of artificial intelligence, medical biotechnology, and pharmaceuticals | ACTIVE | Jul 11, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 24, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 19, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 26, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 26, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 26, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 8, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 28, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 28, 2023 | ALIE | ASSIGNED TO LIE | — |
| Aug 18, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 1, 2023 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 22, 2023 | NWAP | NEW APPLICATION ENTERED | — |